Bundibugyo Virus Outbreak Response Vaccines (BundiVx) - RRPV Consortium

The Office of Biomedical Advanced Research and Development Authority (BARDA), under the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, is soliciting proposals through the Rapid Response Partnership Vehicle (RRPV) Consortium to advance investigational vaccine candidates against the Bundibugyo virus (BDBV) using the Vesicular Stomatitis Virus (VSV) platform. The effort aims to rapidly develop and produce up to 10,000 doses of current Good Manufacturing Practice (cGMP) clinical trial material (CTM), with an option to scale to 100,000 doses, to support a Phase 1 clinical trial during the expected 2026 BDBV outbreak. Work includes manufacturing process development, early regulatory engagement to enable Investigational New Drug (IND) submission, and execution of a clinical trial to assess safety and immunogenicity. Proposals must leverage existing platform efficiencies to accelerate the path to cGMP production and IND filing, with the ultimate goal of identifying viable candidates for further development. The project is structured under a five-year potential period of performance starting in fiscal year 2026, with work planned to support immediate outbreak response and long-term vaccine advancement. Proposals must be submitted via the RRPV BDR Portal by the revised deadline of July 2, 2026, and must adhere to strict formatting and content requirements outlined in five mandatory attachments: Technical Proposal (max 30 pages), Cost Proposal Narrative and Excel Format with working formulas, Statement of Work/Milestone Payment Schedule, and Program/Project Management Plan. The technical proposal must include an executive summary, detailed technical approach, resumes of key personnel, data rights assertions, and evidence of current and pending support. Offers must disclose any organizational conflicts of interest and assert pre-existing or externally developed intellectual property through a defined table, with all rights subject to negotiation. Data deliverables are expected to be provided to the government with unlimited rights unless otherwise agreed upon. The solicitation explicitly prohibits gain-of-function research and requires compliance with U.S. export laws. Evaluation will be based on a best-value determination considering technical approach, relevant corporate and technical experience, program management capability, and cost/price. All submissions must be unclassified and free of proprietary data unless accompanied by a disclosure legend, and no classified, ZIP, or linked content will be accepted. Payment may be structured as Firm Fixed Price, Cost Plus Fixed Fee, Cost Reimbursable, or Cost Share